http://orcid.org/0000-0001-8855-0899
References
- Sehgal VN, Verma P, Sharma S, et al. Acrodermatitis continua of hallopeau: evolution of treatment options: acrodermatitis continua of hallopeau. Int J Dermatol. 2011;50:1195–1211.
- Saunier J, Debarbieux S, Jullien D, et al. Acrodermatitis continua of hallopeau treated successfully with Ustekinumab and Acitretin after failure of tumour necrosis factor blockade and Anakinra. Dermatology. 2015;230:97–100.
- Muggli D, Maul J-T, Anzengruber F, et al. Secukinumab for acrodermatitis continua of hallopeau. JAMA Dermatol. 2017;153:336.
- Balestri R, Rech G, Tasin L, et al. Acrodermatitis continua of hallopeau successfully treated with secukinumab. J Dermatol Treat. 2018;29:3–5.
- Baron JA. Acrodermatitis of hallopeau and erosive oral mucositis successfully treated with secukinumab. JAAD Case Rep. 2017;3:215–218.
- Pilz AC, Roenneberg S, Biedermann T, et al. Ixekizumab for acrodermatitis continua. JDDG: J Deuts Dermatol Gesellschaft. 2018;16:907–910.
- Chatham WW. Chapter 89: Biological modifiers of inflammatory diseases. In: Rich RR, editor. Clinical immunology: Principles and practice. St. Louis, MO: Elsevier; 2019. p. 1201–1203.
- Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018;178:674–681.